frog_in_a_tree
16 Aug 2019
Sunday Telegraph Tip Hello again, The dph share price has pretty much recovered from its fall last and is back on track at 2888p per share. [link] Another very encouraging summary from MF. Dechra has done well for me over the years. Pharmas are likely to be a good defensive buy in the face of Brexit and world tariff wars. BUY. Cheers, Frog in a tree
frog_in_a_tree
14 Jan 2019
Results Clearly I spoke too soon in July as the year’s gains fell off a cliff. Still, the trading update this morning is very positive with business in Europe and the US increasing by 17 to 18%. To me this is a keeper. Despite August’s drop I have profited from it and expect this to continue either as an independent company or as a takeover target. Cheers, Frog in a tree
frog_in_a_tree
03 Sep 2018
Sunday Telegraph Tip Motley Fool also seems positive: "However, I’m also keen on international veterinary pharmaceutical business operator Dechra Pharmaceuticals (LSE: DPH), which released its full-year results today. Whichever way I look at them, the figures are good. Constant exchange rate revenue moved up almost 14% compared to last year and underlying diluted earnings per share shot up nearly 21%. Indeed, the directors underlined their confidence in the outlook by pushing up the total dividend for the year by almost 19%. Facing off the competition So why has the share price fallen a little over 15% today? I suspect the answer to that question can be found in the report under the heading ‘Market Changes’. According to the firm, the veterinary market “is seeing faster change than at any time in its history.†There’s increasing consolidation of veterinary practices and veterinary distributors into larger entities. These enlarged distribution businesses are selling more of their own products and, on top of that, the leading US supplier has moved onto Dechra’s ‘patch’ in the UK and mainland Europe. In a nutshell, Dechra faces more competition than it has been used to. However, the firm’s vibrant research and development pipeline should work alongside an active acquisition programme to keep the firm competing in the market. The directors said in today’s report that the company is “well positioned†to serve the needs of the larger veterinary practice firms that are emerging alongside independent practices. Dechra has “the flexibility to respond quicklyâ€to any ongoing changes within the distribution network. Indeed, today’s figures are encouraging and the new trading year has started well. The directors expect the firm to “continue to outperform.†On balance, I reckon today’s share-price wobble could soon be forgotten as ongoing growth in earnings shines through in the years to come."
sharegardener
03 Sep 2018
Sunday Telegraph Tip Hi FIAT, it may be their statement about bigger US vet groups with large purchasing power getting into Europe and supplying their own drugs (presumably generics) and bypassing companies like DPH - perhaps a veiled warning about future growth prospects. ‘‘Market changes: The veterinary market is seeing faster change than at any time in its history. European practice corporate consolidation is increasing, especially in the UK and some Northern European countries. A recent significant move is the leading USA company taking a small presence in the UK and a significant presence in mainland Europe. Furthermore, veterinary distributors who operate in the majority of major countries in Western Europe and North America are changing and are beginning to increase focus on the sales and marketing of their own products, which is often in conflict with their core historic suppliers. We are also seeing ongoing consolidation of distributors, especially within the USA. The Board of Dechra believes that we are well positioned to support the needs of the larger veterinary practice groups alongside independent practices and that we also have the flexibility to respond quickly to any ongoing changes within the distribution network.’’ Also an FT article today about Dechra planning for ‘hard Brexit’ by relocating some facilities into an EU base. www.ft.com/content/43590aac-af4f-11e8-8d14-6f049d06439c I have been holding for a few years having bought at 675p. [I kept thinking about buying more but regarded them as overpriced at £15!) 15% drop looks overdone although of late there have been some big downgrades of steady companies on relatively trivial ‘bad news’. imho DPH still good for the long term as they are expanding globally. I will have to look in more detail at the figures as adjusted earnings after acquisitions can conceal poor performance. May be a good time to buy in a the bottom of this dip. SG
frog_in_a_tree
03 Sep 2018
Sunday Telegraph Tip I have looked through today’s report and can’t see anything too alarming. There is a smallish increase in debt as a result of acquisitions and reference to contingency planning for Brexit. Otherwise the report is solid and shows the company growing steadily. Cheers, Frog in a tree
Ripley94
03 Sep 2018
Sunday Telegraph Tip DPH… XXXX Top faller today down 15 % looks like a pull back as its been a good chart riser .
frog_in_a_tree
10 Jul 2018
Results Today’s trading update is very positive: Dechra Pharmaceuticals PLC said Tuesday it expects annual revenue up 14% at constant exchange rate after experiencing “strong†trading in line with views. Looking at the chart it shows that the so has appreciated by around 50% since the start of the year. More to come by the looks of it. Cheers, Frog in a tree
II Editor
13 Apr 2018
NEW ARTICLE: The UK smaller companies beating the Brexit blues "The UK smaller companies fund sector is historically a strong performer on a long-term view. Over the past 10 years to 14 February, it has returned more than any other UK sector for its investors. It delivered 181%Â on a total return basis, ..."[link]
frog in a tree
09 Apr 2018
Re: £30 by year end? Now up 200% since investment in February 2015. Mote to come, I think, and with fairly low risk.Cheers,F
frog in a tree
15 Mar 2018
Re: £30 by year end? Checked today and up 27.7% year to date. Very much against the market trend. A winner!Cheers,F
frog in a tree
12 Mar 2018
£30 by year end? Dechra seems to have some price momentum. I think there is a good chance of £30 a pop by the end of the year.F
valeite
27 Feb 2018
Re: Results plenty of optimism here methinks .....investec are liking the growth of the USA where we are gaining momentum .17 x up since the float....wish i'd been there at the beginning but we're going higher .definitely one to hold...it's a great business
Hydrogen Economy
26 Feb 2018
Re: Results Market very unsure what to make of results, big rise early then a dip into loss before heading back up.Always tough with acquisitive businesses to work out whether the returns are adequately covering the capital invested and the accounts are subject to so much adjustment (2017 adjusted EPS is double the reported number) it is more a judgement on the business model and the board on which basis DPH look better than most.H2
frog in a tree
26 Feb 2018
Results Decent results today showing strong growth.Yield is low but there appears to be scope to increase divis as we go along. Cheers,F
valeite
30 Jan 2018
jeffries upgrade buy and target price £26.31 (up from £22.31)
